More health insurance coverage for Synagis injection

Published: 2012-04-12 06:56:00

Updated: 2012-04-12 06:56:00

Starting this month, the government has provided more coverage for Abbott’s Synagis inj. (palivizumab) to reduce respiratory syncytial virus (RSV) infections in infants.

The Ministry of Health and Welfare said Monday that the national health insurance further covers infants with a history of p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK